{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451564452
| IUPAC_name = 6-Ethyl-7-methoxy-5-methyl-2-(5-methyl-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyrimidine
| image = Fasiplon_structure.png
| width = 200

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 106100-65-6
| ATC_prefix = none
| PubChem = 208954
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 62735
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 181047
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XCA050IPGB

<!--Chemical data-->
| C=13 | H=15 | N=5 | O=2 
| molecular_weight = 273.290 g/mol
| smiles = CC1=NC(C2=CN3C(N=C(OC)C(CC)=C3C)=N2)=NO1
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C13H15N5O2/c1-5-9-7(2)18-6-10(11-14-8(3)20-17-11)15-13(18)16-12(9)19-4/h6H,5H2,1-4H3
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = MEBYKPLMXIRYRQ-UHFFFAOYSA-N
}}
'''Fasiplon''' ('''RU 33203''') is a [[nonbenzodiazepine]] [[anxiolytic]] drug from the [[:Category:Imidazopyrimidines|imidazopyrimidine]] family of drugs.

Fasiplon binds strongly to benzodiazepine sites on the [[GABAA receptor|GABA<sub>A</sub>]] [[Receptor (biochemistry)|receptor]] and has similar [[anxiolytic]] effects in animals, but with less [[sedative]] or [[muscle relaxant]] action.<ref name="pmid1648620">{{cite journal |vauthors=Tully WR, Gardner CR, Gillespie RJ, Westwood R |title=2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors |journal=Journal of Medicinal Chemistry |volume=34 |issue=7 |pages=2060â€“7 |date=July 1991 |pmid=1648620 |doi= 10.1021/jm00111a021|url=}}</ref> It was developed by a team at [[Roussel Uclaf]] in the 1990s<ref>US Patent 5869481 Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making</ref>

==References==
<references/>

{{Anxiolytics}}
{{GABAAR PAMs}}

[[Category:Sedatives]]
[[Category:Imidazopyrimidines]]
[[Category:Oxadiazoles]]
[[Category:GABAA receptor positive allosteric modulators]]